Radioimmunotherapy using .alpha.-particles emission

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

167/101

A61K 51/10 (2006.01)

Patent

CA 2034484

The present invention relate to the use of Actinium or one of its daughters in radioimmunotherapy. Also provided are immunoconjugates comprising an isotope, a chelating agent and a slowly localizing antibody. The invention also includes pharma ceutical compositions comprising said immunoconjugates, as well as such compositions comprising one or more scavenging agents. The compositions according to the invention are particularly useful for the treatment of micrometastases in adjuvant therapy. as well as for treatment of localized tumors.

L'invention concerne l'emploi d'Actinium ou d'un des éléments de sa filiation en radioimmunothérapie. L'invention concerne également des immunoconjugués comprenant un isotope, un agent de chélation et un anticorps de localisation lente. L'invention concerne en outre des compositions pharmaceutiques comprenant lesdits immunoconjugués, ainsi que de telles compositions comprenant un ou plusieurs agents d'épuration. Les compositions de l'invention sont particulièrement utiles dans le traitement de micrométastases en thérapie auxiliaire, ainsi que dans le traitement de tumeurs localisées.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Radioimmunotherapy using .alpha.-particles emission does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Radioimmunotherapy using .alpha.-particles emission, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radioimmunotherapy using .alpha.-particles emission will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1701641

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.